View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, May 1 (HealthDay News) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.
Arjen Joosse, M.D., from the Erasmus University Medical Center in the Netherlands, and colleagues examined the female advantage across multiple end points in four phase III randomized adjuvant treatment trials conducted by the European Organization for Research and Treatment of Cancer Melanoma Group. A total of 2,672 patients diagnosed with stage I/II melanoma were included in the analyses.
The researchers identified a consistent and independent survival advantage for women in overall and disease-specific survival (adjusted hazard ratio [aHR], 0.70 and 0.74, respectively), and in time to lymph node and distant metastasis (aHR, 0.70 and 0.69, respectively). The survival advantage for female patients was consistent in both pre- and postmenopausal age groups and across all prognostic subgroups (except possibly for head and neck melanomas).
"Women have a consistent and independent relative advantage in all aspects of the progression of localized melanoma of approximately 30 percent, most likely caused by an underlying biologic sex difference," the authors write.
Full Text (subscription or payment may be required)
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top